Results of the PRESTOCON preclinical trial are in
Results of the PRESTOCON preclinical trial are in
The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.
In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.
These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.
Robert Hendriks MD
Chief Executive Officer, SFI Health
Learn
Research is important, and we want to share it. Our articles distill the complex research and offer expert analysis on the microbiome, brain health and wellbeing.
Could modifying your gut microbiome help manage IBS symptoms?
If you’re one of the millions living with the often-debilitating pain and sometimes embarrassing symptoms of Irritable Bowel Syndrome (IBS), you probably know how challenging this condition can be. You’ll...
Read more
Cognitive health over a lifetime – how it changes and...
Cognitive health describes the ability to learn, think and remember. Not surprisingly, cognitive health is a key component of healthy ageing as it is vital in maintaining a good quality...
Read more
